<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04651855</url>
  </required_header>
  <id_info>
    <org_study_id>ALSTEM</org_study_id>
    <nct_id>NCT04651855</nct_id>
  </id_info>
  <brief_title>The Evaluation of the Effect of Mesenchymal Stem Cells on the Immune System of Patients With ALS</brief_title>
  <acronym>ALSTEM</acronym>
  <official_title>The Evaluation of the Effect of Wharton's Jelly Mesenchymal Stem Cells (WJMSCs) on the Immune System of Patients With Amyotrophic Lateral Sclerosis (ALS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Polski Bank Komorek Macierzystych JSC (PBKM)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Research and Development, Poland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Polski Bank Komorek Macierzystych JSC (PBKM)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety of intrathecal administration of&#xD;
      Wharton's Jelly Mesenchymal Stem Cells (WJMSC) and the impact on the immune system of&#xD;
      patients with Amyotrophic Lateral Sclerosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical Phase: I/II&#xD;
&#xD;
      Population: Patients with Amyotrophic Lateral Sclerosis.&#xD;
&#xD;
      Project Design: One arm, non-blinded, open label study&#xD;
&#xD;
      Planned Sample Size: 20 patients&#xD;
&#xD;
      Investigational Medicinal Product: active IMP - mesenchymal stem cells isolated from&#xD;
      Wharton's jelly&#xD;
&#xD;
      Screening:&#xD;
&#xD;
      Three visits on site to check the eligibility criteria (around 90, 60 and 30 days before&#xD;
      first IMP administration)&#xD;
&#xD;
      Treatment (IMP administration):&#xD;
&#xD;
      Each patient will receive IMP three times: on baseline (day 0), 30 and 60 days after baseline&#xD;
      (+/- 7 days).&#xD;
&#xD;
      Administration route: intrathecal&#xD;
&#xD;
      Follow up:&#xD;
&#xD;
      Duration: 18 months after first IMP administration Four on-site visits (3, 6, 9, 12 months&#xD;
      after first IMP administration) and seven phone visits (4, 5, 7, 8, 10, 11 and 18 months&#xD;
      after first IMP administration)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2020</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of (S)AESI [(Serious) Adverse Event of Special Interest]</measure>
    <time_frame>3 month FU (follow-up)</time_frame>
    <description>(S)AESI are defined as:&#xD;
Meningitis and encephalitis.&#xD;
Toxic encephalopathy.&#xD;
High fever &gt;39⁰C.&#xD;
Epileptic seizures that are not connected to conditions above (meningitis, encephalitis, toxic encephalopathy, high fever).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease progression</measure>
    <time_frame>screening, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 18 month FU</time_frame>
    <description>Disease progression assessed in ALSFRS-R scale (Revised Amyotrophic Lateral Sclerosis Functional Rating Scale). Higher scores mean a better outcome.&#xD;
Minimum: 0 points Maximum: 48 points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function decline</measure>
    <time_frame>screening, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 6, 9 and 12 month FU.</time_frame>
    <description>Pulmonary function decline assessed in spirometry (forced vital capacity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength decline</measure>
    <time_frame>screening, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 6, 9 and 12 month FU</time_frame>
    <description>Muscle strength decline assessed in physical examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Upper motor neuron function</measure>
    <time_frame>screening, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 6, 9 and 12 month FU</time_frame>
    <description>Upper motor neuron function assessed in UMNS scale (Upper Motor Neuron Scale). Best outcome 16 points, worst outcomes: 0 points and 48 points Minimum: 0 points Maximum: 48 points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>screening and 12 month FU</time_frame>
    <description>Cognitive function assessed in ECAS (The Edinburgh Cognitive and Behavioural ALS Screen). Higher scores mean a better outcome.&#xD;
Minimum: 0 points Maximum: 136 points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life changes</measure>
    <time_frame>screening, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 18 month FU</time_frame>
    <description>Quality of life changes, assessed by EQ-5D questionnaire - standardized instrument for measuring generic health status. Higher scores mean a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of defined cytokines, chemokines, growth factors, cystatin C and pNFH (phosphorylated neurofilament heavy chain) level in CSF (Cerebrospinal fluid)</measure>
    <time_frame>run-in visit (-60 day), at baseline and at 1, 2 and 6 month FU (12 month FU optional)</time_frame>
    <description>The change of defined cytokines, chemokines, growth factors, cystatin C and pNFH level assessed in the samples of CSF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of defined cytokines, chemokines and cystatin C level in blood</measure>
    <time_frame>screening visit, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 6, 9 and 12 month FU.</time_frame>
    <description>The change of defined cytokines, chemokines and cystatin C level assessed in the samples of blood serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of creatinine and p75ECD level in urine</measure>
    <time_frame>screening visit, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 6, 9 and 12 month FU.</time_frame>
    <description>The change of creatinine and p75ECD level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle function changes</measure>
    <time_frame>baseline and at 1, 2, 6 and 12 month FU</time_frame>
    <description>Muscle function changes, assessed based on EMG examination (Electrophysiological examination of the muscle - MUNIX - motor unit number estimation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of the brain visualization</measure>
    <time_frame>run-in visit (-60 day), 6 and 12 month FU</time_frame>
    <description>The change of the brain visualization in MRI (T1, T2 and DTI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAE (Serious Adverse Event)/AE (Adverse Event) and (S)AESI</measure>
    <time_frame>18 month FU</time_frame>
    <description>The number of SAE/AE and (S)AESI - defined as in Outcome 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival period to disease progression</measure>
    <time_frame>18 month FU</time_frame>
    <description>The number of days from patients randomization to the end of the patients participation in the trial or to the one of the following:&#xD;
PAV (permanent assisted ventilation)&#xD;
Tracheostomy&#xD;
Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>18 month FU</time_frame>
    <description>Percentage of deaths in the entire study population.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>It is planned that IMP administration will be performed three times for each enrolled patient. IMP administration could be performed only if the patients does not have any contraindications for lumbar puncture.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesenchymal stem cells isolated from Wharton's jelly</intervention_name>
    <description>Intrathecal administration of mesenchymal stem cells</description>
    <arm_group_label>Treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult patients (at least 18 years old)&#xD;
&#xD;
          2. The minimum patient's weight is not less than 40 kg&#xD;
&#xD;
          3. Diagnosis of sporadic ALS, definite or probable, as defined by El Escorial World&#xD;
             Federation of Neurology criteria&#xD;
&#xD;
          4. History of ALS symptoms less than 2 years duration from the first symptoms of the&#xD;
             disease&#xD;
&#xD;
          5. More than 6 months from diagnosis of the disease&#xD;
&#xD;
          6. Disease progression at 6 past months at least 3 points during this period of time&#xD;
&#xD;
          7. ALSFRS-R scale of at least 30 at screening appointment&#xD;
&#xD;
          8. Forced vital capacity &gt;70% of predicted value for age, gender and height&#xD;
&#xD;
          9. Treatment with stable dose of riluzole before baseline visit (for at least 1 month)&#xD;
&#xD;
         10. Capable of providing written informed consent&#xD;
&#xD;
         11. Able to comply with study requirements and willing to follow all study procedures and&#xD;
             follow-up visits&#xD;
&#xD;
         12. Women of child-bearing age and men with partners of child-bearing potential must agree&#xD;
             to use two forms of contraceptive therapy throughout the course of the trial&#xD;
&#xD;
         13. Women of child-bearing age must undergo pregnancy test&#xD;
&#xD;
         14. Polish-language native speakers or patients who are proficient in the Polish language&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy or breastfeeding&#xD;
&#xD;
          2. Tracheostomy&#xD;
&#xD;
          3. Ventilator dependence&#xD;
&#xD;
          4. Renal disease with creatinine &gt;2mg/dl&#xD;
&#xD;
          5. Liver disease with ALT, AST or GGTP 2-fold higher than upper normal limit&#xD;
&#xD;
          6. Positive test for HBV, HCV, HIV with NAT method&#xD;
&#xD;
          7. Positive tests for syphilis&#xD;
&#xD;
          8. Any other clinically significant abnormalities on laboratory evaluation&#xD;
&#xD;
          9. Any condition that would compromise ability of undergoing lumbar puncture&#xD;
&#xD;
         10. Active systemic disease&#xD;
&#xD;
         11. Autoimmune disease (Hashimoto disease under control is allowed)&#xD;
&#xD;
         12. Uncontrolled diabetes&#xD;
&#xD;
         13. Pulmonary disease that could affect interpretation of spirometry&#xD;
&#xD;
         14. Neurological concomitant disease&#xD;
&#xD;
         15. Unstable psychiatric concomitant disease&#xD;
&#xD;
         16. High risk of suicide&#xD;
&#xD;
         17. History of substance abuse within past year&#xD;
&#xD;
         18. History of malignancy, within the previous 5 years, including melanoma with exception&#xD;
             of localized skin cancers&#xD;
&#xD;
         19. Any other clinically significant medical condition that can compromise patient's&#xD;
             safety in the opinion of the investigator&#xD;
&#xD;
         20. Treatment with immunomodulatory drugs (for example immunoglobulins, corticosteroids or&#xD;
             other immunosuppressant) in last 6 months&#xD;
&#xD;
         21. Participation in another clinical trial in last 6 months&#xD;
&#xD;
         22. Previous cellular therapy of any kind&#xD;
&#xD;
         23. Hypersensitivity to any component used in the cell culture&#xD;
&#xD;
         24. Nuchal rigidity and other signs of meningitis&#xD;
&#xD;
         25. Patients on chronic anticoagulation treatment (heparin/ warfarin/acenocoumarol/(N)OAC)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Natalia Żmijewska</last_name>
    <phone>0048-22-436-40-50</phone>
    <email>Natalia.Zmijewska@pbkm.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>JST sp. z o.o.</name>
      <address>
        <city>Częstochowa</city>
        <zip>42-202</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beata Świątkowska-Flis, MD, PhD</last_name>
      <email>beatasflis@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 30, 2020</study_first_submitted>
  <study_first_submitted_qc>December 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2020</study_first_posted>
  <last_update_submitted>December 2, 2020</last_update_submitted>
  <last_update_submitted_qc>December 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>Stem Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

